SGI-110 Clinical Data Presented at EHA for Phase 1 MDS Patients
- SGI-110 clinical data was presented at the European Hematology Association (EHA) Annual Meeting for Phase 1 refractory myelodysplastic syndrome (MDS) patients. For the 15 patients enrolled an overall 40% response rate was achieved with a median duration of response of 92 days. Additionally, the overall Phase 2 patient accrual was reported to be more than 50% complete, on pace to be completed by year end and scheduled to report on at the upcoming American Society of Hematology (ASH), American Association of Cancer Research (AACR) and American Society of Clinical Oncology (ASCO) meetings. Details of the Phase 1 acute myeloid leukemia (AML) data will be presented in an oral session at the European Cancer Congress (ECCO/ESMO) in September 2013.
- ASTX727 was announced to be the next investigational new drug (IND) candidate. ASTX727 will be an oral, hypomethylating agent (HMA) rounding out the epigenetic franchise started by Dacogen® (decitabine) for Injection and SGI-110.
- Preclinical data from AT13387 showed for the first time that front line HSP90 inhibitor combination treatment with targeted therapy delayed the emergence of resistance. Data were presented at the 8 th World Congress of Melanoma.
- Royalty revenue was $16.6 million for the 2013 second quarter compared to $14.4 million for the same prior year period, representing an increase of approximately 15%.
- The Company ended the 2013 second quarter with cash, cash equivalents, and current and non-current marketable securities totaling approximately $134 million, compared to $137 million at March 31, 2013.